One of the standouts of today's afternoon trading session was Viking Therapeutics, which logged a 2.3% performance and outperformed the S&P 500 by 1.0%. The Pharmaceutical stock is now trading at $64.12 per share and may still have upside potential because it is still -43.53% under its average target price of $113.55. Analysts have set target prices ranging from $90.0 to $138.0 dollars per share, and have given the stock an average rating of buy.
The market, on the other hand, is a bit more pessimistic. Viking Therapeutics's short interest -- meaning the percentage of its share float that is being shorted on an expectation of a price decline -- is quite high at 21.5%. The float includes only shares that are available for public trading, and excludes preferred shares.
Short selling involves borrowing shares and then selling them at current market prices. In the successful version of the strategy, the shares are purchased at a lower price at some time in the future. The investor then returns the shares to the lender, and keeps the profit made on the sell/buy transaction.
One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of Viking Therapeutics, institutional investors own 75.3% of the shares. This would indicate a positive sentiment towards the stock among institutions. What does this really tell us?
Institutional investors such as hedge funds, investment firms, and wealth managers devote significant resources to identifying good investments. If they have decided to invest in VKTX, it probably means they believe it is a solid investment choice. But it could also mean they are buying up shares in an effort to acquire the company or get seats on the board of directors. Also bear in mind that institutions are fallible (just maybe not quite as fallible as the average retail investor), so they may simply be wrong when they think they've found a good stock.
In conclusion, we see mixed market sentiment regarding Viking Therapeutics because of an analyst consensus of strong upside potential, a buy rating, an unusually large proportion of its shares sold short, and an average number of institutional investors. At Market Inference, we believe that any investment decision should be preceded by an in-depth analysis of the company's fundamental values and a comparison with similar stocks.
Here's a snapshot of some important facts to keep in mind about VKTX:
-
The stock has trailing 12 month earnings per share (EPS) of $-0.93
-
Viking Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -68.9 compared to the S&P 500 average of 28.21
-
The company has a Price to Book (P/B) ratio of 7.71 in contrast to the S&P 500's average ratio of 4.71
-
Viking Therapeutics is a Health Care company, and the sector average P/E and P/B ratios are 27.61 and 3.69 respectively
